30.27
Stoke Therapeutics Inc Aktie (STOK) Neueste Nachrichten
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting - Business Wire
Advantage Alpha Capital Partners LP Purchases Shares of 17,888 Stoke Therapeutics, Inc. $STOK - MarketBeat
Can Stoke Therapeutics (STOK) Translate Natural History Data Into a Competitive Edge for Dravet Therapy? - simplywall.st
Kennondale Capital Management LLC Grows Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Insider Sell: Adrian Krainer Sells 40,472 Shares of Stoke Therap - GuruFocus
Stoke Therapeutics (NASDAQ:STOK) Sees Unusually-High Trading VolumeShould You Buy? - MarketBeat
Stoke Therapeutics (STOK): Evaluating Valuation Following Key Dravet Syndrome Study Results Published in Neurology - simplywall.st
Jefferies Sticks to Their Buy Rating for Stoke Therapeutics (STOK) - The Globe and Mail
FY2025 Earnings Forecast for STOK Issued By Chardan Capital - MarketBeat
Biogen and Stoke Therapeutics collaborates to develop Dravet syndrome treatment globally - MSN
Stoke Therapeutics Target of Unusually High Options Trading (NASDAQ:STOK) - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Rating Increased to Strong-Buy at Chardan Capital - MarketBeat
(STOK) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Why Stoke Therapeutics Inc. stock remains undervaluedMarket Risk Report & Short-Term High Return Ideas - newser.com
Can Stoke Therapeutics Inc. stock sustain institutional interest2025 Sector Review & Risk Adjusted Buy and Sell Alerts - newser.com
How Stoke Therapeutics Inc. stock valuations compare to rivalsProduct Launch & Verified Momentum Stock Alerts - newser.com
Can Stoke Therapeutics Inc. stock surprise with earnings upsideQuarterly Profit Report & High Conviction Buy Zone Alerts - newser.com
Can Stoke Therapeutics Inc. stock resist sector downturns2025 Top Decliners & Intraday High Probability Alerts - newser.com
Stoke Therapeutics (NASDAQ:STOK) Director Adrian Krainer Sells 40,472 Shares - MarketBeat
Does Stoke Therapeutics Inc. show high probability of reboundJuly 2025 Gainers & Weekly High Return Forecasts - newser.com
Is Stoke Therapeutics Inc. stock a good choice for value investors2025 Sector Review & Weekly High Conviction Ideas - newser.com
Live market analysis of Stoke Therapeutics Inc.July 2025 Gainers & Free Growth Oriented Trading Recommendations - newser.com
Why Stoke Therapeutics Inc. stock attracts high net worth investorsBear Alert & Fast Moving Stock Trade Plans - newser.com
Stoke Therapeutics (NASDAQ:STOK) Trading Up 7.6%Still a Buy? - MarketBeat
Will Stoke Therapeutics Inc. stock maintain momentum in 20252025 Analyst Calls & Risk Managed Investment Signals - newser.com
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - MarketScreener
19,300 Shares in Stoke Therapeutics, Inc. $STOK Purchased by Integrated Quantitative Investments LLC - MarketBeat
Los Angeles Capital Management LLC Makes New $224,000 Investment in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)November 18, 2025 - BioSpace
What technical models suggest about Stoke Therapeutics Inc.’s comeback2025 EndofYear Setup & Verified Trade Idea Suggestions - newser.com
Stoke Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Stoke Therapeutics Director Adrian R. Krainer Sells Over 40,000 Shares - TradingView
Dir Krainer Sells 40,472 ($1.1M) Of Stoke Therapeutics Inc [STOK] - TradingView
[Form 4] Stoke Therapeutics, Inc. Insider Trading Activity - Stock Titan
Could Endpoint Choices in the EMPEROR Trial Reveal a Strategic Shift for Stoke Therapeutics (STOK)? - simplywall.st
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):